The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2016 | Mechanism of action of daratumumab
Niels van de Donk, MD, PhD from the University Medical Center, Amsterdam, Netherlands discusses the mechanism of action of daratumumab at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark. Daratumumab induces antibody-dependent cellular cytotoxicity (ACC), antibody-dependent cellular cell-mediated phagocytosis (ADCP) as well as complement-dependent cytotoxicity (CDC). Dr van de Donk further explains that daratumumab has been shown to eliminate regulatory T-cells, regulatory B-cells and myeloid-derived suppressor cells. The elimination of various immune suppressors may help the T-cell system to recover.
